cellsciences.com

[Ala³¹]IGF-I Recombinant Human (Receptor Grade)

Catalog No:	AIU020 Quantity: 20 μg AIU100 100 μg AIM001 1.0 mg
Description:	Human [Ala ³¹]Insulin-like Growth Factor-I ([Ala ³¹]IGF-I) is a 70 amino acid analog of human IGF-I comprising the complete human IGF-I sequence with the substitution of an Ala for Tyr at position 31 (hence [Ala ³¹]). Scientists have engineered this analog with the express purpose of changing biological activity. Human [Ala ³¹]IGF-I has normal binding affinity for acid-stripped human serum binding proteins. However compared to human IGF-I, human [Ala ³¹]IGF-I has reduced binding to the Type 1 IGF receptor and to the insulin receptor. Human [Ala ³¹]IGF-I binds to these receptors slightly more strongly than human [Leu ²⁴]IGF-I or human [Leu ⁶⁰]IGF-I.
References:	Forbes, B.E. et al. (2002) Eur. J. Biochem., 269 , 961-968
	Milner, S. J. et al. (1995) Biochem. J., 308 , 865-871
Source:	Produced recombinantly in <i>E. coli</i> .
Purity:	Greater than 95 % (by HPLC and N-terminal sequence analysis)
Molecular Weight:	7.557 kDa – confirmed by Mass Spectometry
N-terminal sequence analysis:	5 residues Greater than 95 % single sequence
Biological Activity:	Type 1 IGF receptor binding assay: ED_{50} Greater than 10 ng/ml
	IGF binding protein assay: ED_{50} Less than 10 ng/ml
	Stimulation of protein synthesis in rat L6 myoblasts: ED_{50} Less than 50 ng/ml
Endotoxin:	Less than 0.1 EU/ μg
State and appearance:	Lyophilized white powder.
	Dried from 0.1 M acetic acid and stored under dry nitrogen at a slight vacuum (-25 kPa)
Storage/Stability:	At least 2 years at 2 - 4°C (lyophilized)
Reconstitution:	Refer to Protocol 1000: Handling of IGF-I, IGF-II and IGF Analogs

NOT FOR HUMAN USE. FOR RESEARCH ONLY. NOT FOR DIAGNOSTIC OR THERAPEUTIC USE.

